Transonic and EUROGINE ingredients: water, propylene glycol, carbomer, diazolidinyl urea, methyl and propyl parabens, and disodium ethylenediaminetetraacetic acid. How to cite this article: Martínez Ant on MD, J auregui I, Gal an C, et al. Two cases of allergic contact dermatitis to different elements in identical ultrasound gels. Contact
Background
Fixed drug eruption (FDE) is a characteristic form of intraepidermal CD8+ T cell‐mediated drug reaction, with repeated appearance of isolated or multiple skin lesions in the same location after receiving the offending drug. Non‐steroidal anti‐inflammatory drugs (NSAID) are the most common cause. Selective inhibitors of inducible cyclooxygenase 2 (COX‐2) provoke a lesser degree of allergic or idiosyncratic adverse reactions than conventional NSAID, but they can cause skin reactions of variable severity.
Objective
Etoricoxib has been related to a variety of unusual skin reactions, including several reports of FDE.
Methods
We perfomed epicutaneous test to diagnose patients with suspected etoricoxib fixe drug rash due to clinical features and reproducibility on at least two occasions.
Results
We present seven new cases of etoricoxib‐induced fixed drug eruption, with a diagnosis based on clinical presentation. This diagnosis was confirmed by an etoricoxib‐positive lesional patch test in six cases and by a positive low‐dose oral challenge in the other one. Two patients showed negative patch tests with celecoxib (10% in pet.) on the residual lesions, and oral tolerance was confirmed in one.
Conclusion
To our knowledge, this is the largest series on FDE induced by etoricoxib reported to date.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.